Clinical trials: Moderate to Severe Asthma
Asthma
Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma
Study D9181C00001 is a Phase II, randomised, double-blind, placebo-controlled, parallel group, proof of concept study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of MEDI3506 in adult participants…
- Trial name
- FRONTIER-3 (NCT04570657)
- Testing
- MEDI3506
- Where
- 65 sites in United States, Argentina and 5 more
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Asthma
A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma
This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of participants with moderate to severe asthma.
- Trial name
- NCT07436221
- Testing
- AK139
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Akeso
Asthma
Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma
The purpose of this study is to evaluate the safety and tolerability of MN-221 at two different dosing rates administered through a continuous infusion in subjects diagnosed with moderate to severe asthma.
- Trial name
- NCT00679263
- Testing
- MN-221
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- MediciNova
Asthma
Study of CM512 Injection in Subjects With Moderate-to-severe Asthma
This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with…
- Trial name
- NCT07011524
- Testing
- CM512 injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Keymed Biosciences Co.Ltd
Asthma
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week…
- Trial name
- AJAX (NCT06020014)
- Testing
- AZD4604
- Where
- 124 sites in United States, Argentina and 16 more
- Volunteers
- 339 people
- Sponsor
- AstraZeneca
Asthma Copd
A Multicenter, Randomized, Parallel, Two-Period, Non-Inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment
A phase III study, multicenter, randomized, parallel, open, two-period, comparative non-inferiority of Eurofarma versus Alenia® in the treatment of moderate to severe persistent asthma with and without obstructive pulmonary…
- Trial name
- ESPIRE (NCT04233190)
- Testing
- Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg
- Where
- Brazil
- Volunteers
- 472 people
- Sponsor
- Eurofarma Laboratorios S.A.
Intrinsic Asthma, Allergic Asthma
The Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children
The aim of investigator´s clinical trial is to investigate 52 patients aged three to five years with viral-induced asthma and 52 patients aged three to five years with allergic asthma.
- Conditions
- Intrinsic Asthma, Allergic Asthma, Allergy, Bronchial Hyperresponsiveness
- Trial name
- BHR (NCT01144910)
- Testing
- methacholine challenge test
- Where
- Germany
- Sponsor
- Johann Wolfgang Goethe University Hospital
Asthma
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled…
- Trial name
- FLASH (NCT05251259)
- Testing
- Atuliflapon
- Where
- 234 sites in United States, Argentina and 18 more
- Volunteers
- 670 people
- Sponsor
- AstraZeneca
Lung Diseases
Patterns of Neurocircuitry Activation In Severe Asthma
The overall purpose of the study is to compare the patterns of neurocircuitry activation in severe asthmatics vs. mild to moderate and healthy controls.
- Trial name
- PANISA (NCT03230188)
- Testing
- functional Magnetic Resonance Imaging (research grade), Cognitive Function Testing (non-diagnostic), Asthma and Psychological Questionnaires (non-diagnostic)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Wisconsin, Madison